Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination

Lee-Hwa Tai¹, Jiqing Zhang¹23, and Rebecca C Auer¹45*

¹Centre for Innovative Cancer Research; Ottawa Hospital Research Institute; Ottawa, Canada; ²Department of Cellular and Molecular Medicine; University of Ottawa; Ottawa, Canada; ³Department of Neurosurgery; The Second Hospital of Shandong University; Shandong, China; ⁴Department of Surgery; University of Ottawa; Ottawa, Canada; ⁵Department of Biochemistry, Microbiology, and Immunology; University of Ottawa; Ottawa, Canada

Keywords: cancer metastases, influenza vaccine, immunosuppression, natural killer cells, surgical stress

Abbreviations: IFNα, interferon α; IFNγ, interferon γ; NK, natural killer; PBMC, peripheral blood mononuclear cell

Surgical resection is often required for the treatment of localized solid malignancies. However, even upon complete resection, many patients harbor microscopic residual disease and ultimately die of recurrence.¹ Surgeons have long suspected that the physiological response to surgery facilitates cancer growth and metastatic dissemination, and numerous studies have established that the postoperative period provides an ideal setting for the formation of metastases.²³ Nevertheless, the perioperative period may provide a therapeutic window that has largely been ignored, and to date there are no cancer therapies specifically targeting this period.⁴⁶

Natural killer (NK) cells play a critical role in tumor clearance in vivo, but their functions are markedly impaired upon surgery.⁶ Postoperative NK-cell suppression correlates with increased metastatic burden in animal models, while in cancer patients reduced NK-cell activity during the postoperative period has been associated with a high rate of disease recurrence and mortality.⁴ Several mechanisms are thought to be responsible for the postoperative dysfunction of NK cells, including the secretion of catecholamines, prostaglandins, and immunosuppressive cytokines such as transforming growth factor β (TGFβ), interleukin (IL)-6, and IL-10, but mechanistic details on this process are lacking.⁵⁶ (Fig. 1). We have previously demonstrated that surgery causes a global dysfunction in NK cells.⁴ Based on these findings, we hypothesized that non-specific stimulation of the immune system, such as that obtained with an inactivated prophylactic vaccine against an infectious pathogen, could prevent postoperative NK-cell dysfunction and attenuate the metastatic dissemination of malignant cells if administered before surgery.

And the Winner is... Influenza Vaccine

To explore this hypothesis, we assessed a panel of routinely used prophylactic vaccines, including preparations against influenza, meningitis, measles/mumps/rubella, diphtheria/tetanus/pertussis/polio, pneumonia, and influenza for their ability to activate NK cells, measured by CD69 expression and enhance their function (measured by cytotoxicity assay and interferon IFNγ secretion). The influenza vaccine turned out to be the most potent activator of NK cells among the prophylactic vaccines tested, although, not unexpectedly, inoculating mice with live replicating viruses (such as vaccinia virus) induced even higher levels of NK-cell cytotoxicity. Using murine models of experimental (B16 melanoma), or spontaneous (4T1 breast carcinoma) metastasis, and surgical stress (laparotomy and nephrectomy), we demonstrated that the preoperative delivery of a single dose of influenza vaccine resulted in a dramatic reduction in the metastatic dissemination of cancer cells to the lungs.⁹

Influenza Vaccine Prevents Postoperative Metastases by Enhancing NK-cell Function Through IFNα

In order to confirm that NK cells play a critical role in preventing postoperative metastases upon the preoperative administration of an influenza vaccine, we pharmacologically depleted NK cells and observed a complete abrogation of the therapeutic effect of influenza vaccination. By evaluating a panel of cytokines that are known to directly or indirectly activate NK cells, we observed that IFNα levels...
underwent the most dramatic increase upon vaccination. We also observed that low dose preoperative IFNα was able to rescue surgery-induced NK-cell dysfunction and control postoperative metastatic dissemination to the same degree as influenza vaccination. The central role for IFNα was further confirmed by that fact the influenza vaccination was not able to increase postoperative NK-cell activity or attenuate postoperative metastases in IFNα receptor-deficient mice. Moreover, a Type 1 IFN-blocking antibody prevented the influenza vaccine from activating NK cells among peripheral blood mononuclear cells (PBMCs) isolated from healthy people. While our study did not explore the role of dendritic cells in the production of IFNα upon influenza vaccination, it is very likely that these cells represent the primary source of IFNα, resulting in secondary NK-cell stimulation (Fig. 1).

**Timing is Everything**

We hypothesized that, in order to exhibit maximal efficacy against postoperative metastases, the influenza vaccine had to be delivered so that the stimulation of NK cells would be maximal during the immediate postoperative period, when NK-cell suppression is most pronounced. This was indeed the case. NK-cell activation by preoperative influenza vaccination was maximal 1 d after administration, decreasing to baseline levels over 3–5 d. When the influenza vaccine was administered 5 d prior to surgery, we observed a significant reduction in its ability to prevent postoperative metastases. Moreover, despite the fact that repeated dosing of the influenza vaccine could re-activate NK cells to the same degree as the initial dose, adding multiple postoperative courses of vaccination did not further reduce the number of metastases. Data from cancer patients who underwent surgery also confirm that the timing of vaccination is critical for its antineoplastic effects. In 4/4 patients, NK cells isolated prior to surgical resection exhibited increased activity upon exposure to the influenza vaccine ex vivo. Conversely, only in 1/4 patients a similar activation could be documented on NK cells that were isolated 1 d after surgery. This suggests that the surgery-induced dysfunction of NK cells can be prevented but not reversed by influenza vaccines. In individuals receiving a flu shot as part of a vaccination campaign, NK-cell activation peaked 1–2 d after immunization. Taken together, these results suggest that influenza vaccination should be
delivered one day before surgery, allowing sufficient time for the optimal activation of NK cells prior to surgical stress.9

Influenza: Dirty but Safe

There is an argument to be made for administering IFNα prior to cancer surgery, since our results strongly indicate that it is responsible for the beneficial effects of preoperative influenza vaccination. IFNα might generate well-defined conditions to achieve NK-cell stimulation and overcome the individual variability in the responses to influenza vaccination. This strategy has previously been explored in a handful of clinical studies, demonstrating increased NK-cell activity with acceptable toxicity, but these trials were not powered to explore clinical outcomes.10 This said, the safety profile of influenza vaccination is unparalleled. This prophylactic intervention has been used in national vaccination campaigns, is widely available, cost effective and acceptable to patients. After all, it’s only a flu shot.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References
1. Coffey JC, Wang JH, Smith MJ, Boucher-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003; 4:760-8; PMID:14662433; http://dx.doi.org/10.1016/S1470-2045(03)01282-8
2. Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer surgery. Am J Surg 1994; 167:174-9; PMID:8311130; http://dx.doi.org/10.1016/0002-9610(94)90070-1
3. Goldfarb Y, Sonski L, Beniah M, Levi B, Melamed R, Ben-Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 2011; 253:798-810; PMID:21370023; http://dx.doi.org/10.1097/SLA.0b013e318211d7b5
4. Tai LH, de Souza CT, Belanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 2013; 73:97-107; PMID:23090117; http://dx.doi.org/10.1158/0008-5472.CAN-12-1993
5. Menger MD, Vollmar B. Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch Surg 2004; 389:875-84; PMID:15173946; http://dx.doi.org/10.1007/s00423-004-0472-0
6. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10:972-92; PMID:14527919; http://dx.doi.org/10.1245/ASO.2003.02.007
7. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999; 80:880-8; PMID:10074922; http://dx.doi.org/10.1002/(SICI)1097-0215(19990415)80:6<880::AID-IJC143>3.0.CO;2-Y
8. Hensler T, Hecker H, Heeg K, Heidecke CD, Barretts H, Barthlen W, Wagner H, Siewert JR, Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997; 65:2283-91; PMID:9169765
9. Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, Salis S, Adair RA, Mahmoud AB, Sad S, et al. Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells. Clin Cancer Res 2013; 19:5104-15; PMID:23881927; http://dx.doi.org/10.1158/1078-0432.CCR-13-0246
10. Oosterling SJ, van der Bij GJ, Mels AK, Meijer S, van Egmond M, van Leeuwen PA. Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. Histol Histopathol 2006; 21:753-60; PMID:16598674